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Exacerbation of radiocontrast nephrotoxicity by endothelin Radiocontrast nephrotoxicity is a common and impor-
receptor antagonism. tant cause of hospital-acquired renal insufficiency [1–4].
Background. Endothelin is a potent vasoconstrictor that has Although the pathogenesis of radiocontrast nephrotoxic-
been implicated in the pathogenesis of radiocontrast nephro- ity is not clearly defined, an imbalance between vasodila-toxicity. Endothelin antagonists may reduce the renal hemody-
tory and vasoconstrictive factors has been proposed asnamic abnormalities following radiocontrast administration.
a mechanism for causing renal medullary ischemia [5].Methods. One hundred fifty-eight patients with chronic renal
insufficiency [mean serum creatinine 6 SD 5 2.7 6 1.0 mg/dL Endothelin is an endogenous peptide with potent va-
(242.3 to 6 92.8 mmol/L)] and undergoing cardiac angiography soconstrictor effects, including preferential reduction of
were randomized to receive either a mixed endothelin A and intrarenal blood flow [6, 7]. In animals, significant in-
B receptor antagonist, SB 290670, or placebo. All patients creases in both plasma and urinary endothelin levels
received intravenous hydration with 0.45% saline before and
have been observed during and after intravenous radio-after radiocontrast administration. Serum creatinine concen-
contrast administration [8]. Furthermore, endothelin re-trations were measured at baseline, 24 hours, 48 hours, and 3
ceptor antagonists have been found to prevent renalto 5 days after radiocontrast administration. The primary end
point was the mean change in serum creatinine concentration vasoconstriction in animal models of radiocontrast neph-
from baseline at 48 hours; the secondary end point was the rotoxicity [9, 10]. However, to our knowledge, there have
incidence of radiocontrast nephrotoxicity, defined as an increase been no studies of these antagonists for the prevention
in serum creatinine of $0.5 mg/dL (44 mmol/L) or $ 25% from of radiocontrast nephrotoxicity in humans.
baseline within 48 hours of radiocontrast administration.
SB 209670 [(1RS-2SR, 3RS)-3-(2-carboxymethoxy-4-Results. The mean increase in serum creatinine 48 hours
methoxy-phenyl)-5-(prop-1-yloxy)indane-2-carboxylicafter angiography was higher in the SB 209670 group [0.7 6
acid; SmithKline Beecham Pharmaceuticals, King of Prus-0.7 mg/dL (63.5 6 58.6 mmol/L)] than in the placebo group
[0.4 6 0.6 mg/dL (33.6 6 55.1 mmol/L), P 5 0.002]. The inci- sia, PA, USA] is a novel, nonpeptide-mixed endothelin
dence of radiocontrast nephrotoxicity was also higher in the receptor A and B (ETA and ETB) antagonist. In animals,
SB 209670 group (56%) compared with placebo (29%, P 5 infusion of SB 209670 prior to radiocontrast administra-
0.002). This negative effect of SB 209670 was apparent in both tion resulted in a significant increase in renal blood flow
diabetic and nondiabetic patients. Adverse effects, especially
and attenuated the reduction in glomerular filtration ratehypotension or decreased blood pressure, were more common
[10]. This multicenter, prospective, randomized studyin the SB 209670 group.
was performed to determine whether or not the adminis-Conclusions. In patients with chronic renal insufficiency who
were undergoing cardiac angiography, endothelin receptor an- tration of SB 209670 prevents increases in serum creati-
tagonism with SB 209670 and intravenous hydration exacerbate nine concentration and reduces the incidence of radio-
radiocontrast nephrotoxicity compared with hydration alone. contrast nephrotoxicity in a group of patients at high
risk for this complication while undergoing cardiac angi-
ography.
1Refer to the Appendix for investigators and participating centers.
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raphy with serum creatinine $2.0 mg/dL (176.8 mmol/L) Study end points
within 48 hours prior to radiocontrast administration The primary end point of the study was the mean
were eligible for the study. Exclusion criteria were a change in serum creatinine from baseline value at 48
supine blood pressure of ,100/70 mm Hg or a heart rate hours after radiocontrast administration. The predefined
of .100 beats per minute at baseline, acute renal failure, secondary end points were the incidence of radiocontrast
chronic renal failure requiring dialysis, inability to ad- nephrotoxicity, peak serum creatinine level, and dura-
here to the hydration regimen, diuretic therapy within tion of hospitalization. Radiocontrast nephrotoxicity was
12 hours or during infusion of study drug, dopamine defined as a $0.5 mg/dL (44 mmol/L) or $25% increase
therapy within six hours or during infusion of study drug, in serum creatinine concentration from baseline within
administration of nonsteroidal anti-inflammatory drugs 48 hours of radiocontrast administration.
other than aspirin (#325 mg per day) within 24 hours
of study drug, uncontrolled cardiac arrhythmia, hepatic Statistical analysis
dysfunction, cerebrovascular accident within one week, Randomization was performed locally by means of
and women of child-bearing potential. All patients re- sealed envelopes. A hospital pharmacist was designated
ceived $50 ml of intra-arterial low osmolar radiocon- as the unblinded third party for preparation of the study
trast. The indications for angiography and the choice drugs and random assignment of treatment.
of low osmolar radiocontrast were determined by each A sample size of 172 patients (86 per treatment group)
patient’s cardiologist and were based on clinical needs. was initially planned in order to detect a 0.5 mg/dL
The protocol was approved by the institutional review (44 mmol/L) difference in serum creatinine between SB
board at each institution, and all patients gave written 209670 and placebo, assuming a standard deviation of
informed consent. change in serum creatinine from baseline of 0.8 mg/dL
(71 mmol/L) for both treatment groups, with 90% powerStudy protocol
and a two-tailed significance level of 0.05.
The study design involved a double-blind random as-
Data are reported as mean values 6 SD for continuous
signment of patients to receive either SB 209670 (100
variables and as percentages for discrete variables. Con-
mg/kg of ideal body weight over 10 min, followed by an
tinuous variables were analyzed by two-tailed t-test andinfusion of 1.0 mg/kg per min) or placebo. This dose of
discrete variables by the chi-square test or Fisher’s exactSB 209670 was found to result in a steady-state plasma
test. A P value of less than 0.05 was considered statisti-SB 209670 concentration of approximately 1200 ng/mL.
cally significant. The percentage of patients with an in-In prior studies, this dose was the highest tolerated dose
crease in serum creatinine of 0.5 mg/dL (44 mmol/L) orin older or hypertensive patients and resulted in a modest
$25% increase over baseline after radiocontrast admin-reduction in blood pressure in patients with essential
istration was evaluated by Cochran-Mantel-Haenszelhypertension (abstract; Am J Hypertens 11:171A, 1998).
methodology with center as strata. The change in serumAll patients received 0.45% saline intravenously at a rate
creatinine concentration and peak serum creatinine con-of 1 mL/kg of body weight per hour beginning 2 to 12
centration was analyzed by a general linear model.hours prior to and continuing for at least 12 hours after
The serum creatinine level at 48 hours after radiocon-radiocontrast administration.
trast administration, the change in serum creatinine atSB 209679 or placebo was begun 30 to 150 minutes
48 hours from baseline value, and the incidence of neph-before radiocontrast administration and was infused for
rotoxicity for each treatment group were compared sepa-12 hours; interventions for coronary artery disease were
rately for diabetic versus nondiabetic patients. Standardpostponed for 48 hours after radiocontrast administra-
t-test analyses were used in comparing the creatininetion unless necessitated by refractory ischemia. Infusion
values. Logistic regression was used for the comparisonof the study drug was terminated early for the develop-
of nephrotoxicity.ment of heart rate .130 beats per minute, hypotension
In order to assess the effects of treatment with SBnot responsive to intravenous fluids (systolic blood pres-
209670 and diabetes, four models were created for eachsure ,80 mm Hg or a decrease in systolic or diastolic
end point. One model used the presence or absence ofblood pressure .30 mm Hg), symptoms or signs of organ
diabetes as the predictor, while another model used thehypoperfusion, need for protocol-prohibited medica-
treatment group as the predictor in order to evaluatetions, or any other severe adverse effect. Vital signs were
the univariable effects of these factors on the end points.measured at baseline, prior to initiation of study medica-
The third model assessed both diabetes and treatmenttion, every 10 minutes for the first hour, every hour for
group for any independent effect. The final model in-the next 11 hours, and then every 4 hours for 12 hours.
cluded diabetes, treatment group and the interaction ofSerum creatinine measurements were performed at base-
diabetes and treatment to test for a differential treatmentline and at 24 hours, 48 hours, and 3 to 5 days after the
initiation of study medication. effect in diabetic versus nondiabetic patients. General
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Table 1. Baseline characteristics of the two treatment groups group (Table 2). At 24 hours, the mean increase in serum
creatinine concentration was 0.3 6 0.4 mg/dL (30.0 6SB 209670 Placebo
Characteristic (N 5 77) (N 5 81) 32.1 mmol/L) for the SB 209670 group compared with
Age years 64.6612.1 66.6610.1 0.1 6 0.3 mg/dL (9.6 6 25.8 mmol/L) for the placebo
Sex male/female 51/26 59/22 group (P 5 0.00003); at 48 hours, the mean increase
Weight kg 84.7618.4 84.3619.6
in serum creatinine concentration was 0.7 6 0.7 mg/dLBlood pressure
Systolic mm Hg 148626 148626 (63.5 6 58.6 mmol/L) compared with 0.4 6 0.6 mg/dL
Diastolic mm Hg 79614 75612 (33.6 6 55.1 mmol/L), respectively (P 5 0.002).
Serum creatinine mg/dL 2.760.9 2.861.1
At 48 hours after cardiac angiography, the incidenceDiabetes mellitus 53 (69) 47 (58)
Congestive heart failure 37 (48) 44 (54) of radiocontrast nephrotoxicity was significantly higher
Calcium-channel antagonist therapy 36 (44) 39 (48) in patients who received SB 209670 compared with those
Volume of radiocontrast agent mL 104.0664.8 122.4686.2
who received placebo (56 vs. 29%, P 5 0.002), reflectingDuration of IV hydration hours 21.7610.9 24.1614.8
a relative risk of 1.82 (95% CI, 1.19 to 2.77). There wasData are presented as mean 6 SD.
no difference in duration of hospitalization between SB
209670 and placebo groups (10.8 6 8.8 vs. 10.3 6 8.2
days, respectively, P 5 0.430).
Of the total study population, 100 out of 158 patientslinear modeling techniques were used for the continuous
had diabetes mellitus; of the patients included in thecreatinine value end points. Logistic regression modeling
analysis of efficacy, 84 out of 132 had diabetes mellitus.techniques were used for nephrotoxicity. All analyses
Baseline serum creatinine levels were similar for diabeticwere performed with SAS version 6.08 (SAS Institute,
versus nondiabetic patients [2.9 6 1.0 mg/dL (252.6 6Cary, NC, USA).
90.1 mmol/L) vs. 2.6 6 1.0 mg/dL (227.3 6 85.2 mmol/L),
respectively, P 5 0.131]. Radiocontrast nephrotoxicity
occurred in 45 out of 84 (54%) patients with diabetesRESULTS
mellitus, and in 11 out of 48 (23%) nondiabetic patients
One hundred fifty-eight patients were randomized in (P , 0.001). Among patients with diabetes, the mean
this study. At 48 hours after cardiac angiography, 132 increase in serum creatinine concentration and the inci-
out of 158 patients had serum creatinine measurements dence of radiocontrast nephrotoxicity were significantly
available for the analysis of efficacy. greater for the SB 209670 group compared with placebo
Table 1 shows the baseline characteristics of the two (Table 3). Furthermore, diabetic patients who received
study groups; no significant differences were detected SB 209670 had an absolute increase in serum creatinine
between the groups. The number of patients with diabe- and an incidence of radiocontrast nephrotoxicity that
tes mellitus or congestive heart failure was similar in both was significantly higher than nondiabetics who received
groups, as was the number receiving calcium-channel SB 209670.
When the relative increases in serum creatinine wereantagonists before angiography. The volume of radio-
evaluated with respect to diabetic status, SB 209670 re-contrast agent given in the two groups was also similar.
sulted in a 45% increase among diabetic patients com-Baseline serum creatinine concentrations were similar
pared with a 43% increase among nondiabetic patients.for the two treatment groups (P 5 0.842). At 48 hours
Logistic regression modeling of the interaction betweenafter radiocontrast administration, there was a trend to-
treatment and diabetes on the end point of radiocontrastward a higher mean serum creatinine concentration in
nephrotoxicity demonstrated that the effect of SB 209670the SB 209670 group compared with the placebo group
on the incidence of radiocontrast nephrotoxicity was not[3.5 6 1.2 mg/dL (308.9 6 104.9 mmol/L) vs. 3.1 6 1.2
statistically different in diabetic versus nondiabetic pa-mg/dL (277.1 6 105.2 mmol/L), respectively, P 5 0.062].
tients (P 5 0.356).
At three to five days follow-up after cardiac angiography,
Adverse effects were more frequent in the SB 209670
there was no significant difference in the mean serum treatment group compared with placebo (Table 4). In
creatinine concentration between patients treated with the SB 209670 group, nine (12%) patients were with-
SB 209670 and those who received placebo [3.6 mg/dL drawn from the study during the 48-hour period after
(315.4 mmol/L) vs. 3.4 mg/dL (301.5 mmol/L), respec- radiocontrast administration because of adverse events
tively, P 5 0.880]. The mean time to peak serum creati- compared with three (4%) patients in the placebo group.
nine concentration was 57.1 hours in the SB 209670 group In the SB 209670 treatment group, decreased blood pres-
and 56.2 hours in the placebo group (P 5 0.910). sure (either a transient decrease or hypotension as de-
For the primary end point, the increase in serum creati- fined earlier in this article) occurred in 14 (18%) patients;
nine concentration was significantly greater at both 24 in the placebo group, these adverse effects occurred in
eight (10%). Among the 14 out of 77 patients in theand 48 hours in the SB 209670 group than in the placebo
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Table 2. Change in serum creatinine for the treatment groups
SB 209670 Mean change Placebo Mean change
SCr from baseline SCr from baseline
N mg/dL P valuea
Baseline 158 2.760.9 — 2.861.2 — —
24 hours 148 3.161.1 0.360.4 (112.9%) 2.861.0 0.160.3 (14.4%) ,0.001
48 hours 132 3.561.2 0.760.7 (127.8%) 3.161.2 0.460.6 (115.2%) 0.002
Data are presented as mean 6 SD. SCr is serum creatinine concentration.
aP value for the comparison of mean change from baseline between the two groups
Table 3. Serum creatinine concentration at baseline and 48 h after radiocontrast administration according to treatment group and presence
or absence of diabetes mellitus
Diabetes present (N 5 84) Diabetes absent (N 5 48)
SB 209670 Placebo SB 209670 Placebo
(N 5 45) (N 5 39) P value (N 5 19) (N 5 29) P value
Baseline serum creatinine mg/dL 2.961.0 2.961.0 0.962 2.661.0 2.661.0 0.942
Serum creatinine 48 h after radiocontrast administration mg/dL 3.761.2 3.361.3 0.140 3.061.0 2.861.1 0.620
Increase in serum creatinine at 48 h mg/dL 0.960.7 0.560.7 0.012 0.460.4 0.260.5 0.228
Incidence of radiocontrast nephrotoxicity % 30/45 (67%) 15/39 (39%) 0.009 6/19 (32%) 5/29 (17%) 0.252
Data are presented as mean 6 SD.
SB 209670 treatment group who developed either frank vasoconstrictor action of endothelins in human blood
hypotension or decreased blood pressure, the mean in- vessels [20]. The relative contribution of each subtype
crease in serum creatinine concentration at 48 hours after to the vasopressor effects of endothelins is believed to
radiocontrast administration was 0.5 6 0.5 mg/dL (42.8 6 vary depending on the vascular bed in question.
42.1 mmol/L), compared with 0.8 6 0.7 mg/dL (73.1 6 Because of the potent effects of endothelins on renal
60.7 mmol/L) in 63 out of 77 patients who did not experi- blood flow [7], endothelin receptor antagonists may offer
ence this complication (P 5 0.080). potential new therapies for renal diseases in which vaso-
constriction may play a role. For example, ETA-selective
and mixed antagonists have been shown to improve theDISCUSSION
renal blood flow and glomerular filtration rate in animalRadiocontrast nephrotoxicity is a common cause of
models of cyclosporine-induced renal failure [21, 22]. SBhospital-acquired renal failure and is a well-recognized
209670, a nonselective endothelin receptor antagonist,complication of cardiac angiography. Depending on the
has been found in prior animal studies to increase renaldefinition of radiocontrast nephrotoxicity and the patient
blood flow after radiocontrast administration [9] andpopulation, the incidence has been reported to occur in
0 to 58% of patients after radiocontrast administration thus was evaluated in the present study for the preven-
[11–14]. Furthermore, patients who develop radiocon- tion of radiocontrast nephrotoxicity in patients undergo-
trast nephrotoxicity have a significantly higher mortality ing cardiac angiography.
rate compared with patients who do not develop this In this study, the mean increase in serum creatinine
complication, even after adjustment for differences in concentration was significantly higher in patients who
comorbidity [4]. A number of therapies, particularly the received SB 209670 compared with those who received
use of intravenous hydration [15], diuretic agents [15], placebo. Similarly, the incidence of radiocontrast neph-
and nonionic radiocontrast media [16, 17], have been rotoxicity was not reduced by the use of SB 209670 in
evaluated for reducing the risk of this complication. In patients with pre-existing renal dysfunction. In contrast,
this study, we evaluated a novel endothelin receptor
the incidence of radiocontrast nephrotoxicity at 48 hoursantagonist in patients at high risk for developing radio-
after radiocontrast administration was significantly highercontrast nephrotoxicity after cardiac angiography.
in patients who received SB 209670 compared with pa-Endothelins, a peptide family of closely related iso-
tients who received placebo (56 vs. 29%, respectively).forms, act on two distinct subtypes of receptors called
Importantly, the negative effect of SB 209670 was ap-ETA and ETB receptors [18, 19]. In the past, ETA recep-
parent in both diabetic and nondiabetic patients whotors were believed to mediate the vasoconstrictor effects
received the endothelin receptor antagonist. Althoughof endothelins, whereas ETB receptors were thought to
diabetic patients who were treated with SB 209670 hadproduce vasodilatory effects. However, both subtypes of
receptors have recently been found to be involved in the a significantly higher increase in serum creatinine and
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Table 4. Most frequent adverse effects in the two treatment groups lack of benefit of SB 209670 on the incidence of radiocon-
trast nephrotoxicity raises questions as to the role ofSB 209670 Placebo
Adverse effect (N 5 77) (N 5 81) P value endothelin in the pathogenesis of radiocontrast nephro-
Hypotension 11 (14) 7 (9) 0.321 toxicity.
Headache 5 (6) 1 (1) 0.110 Other vasodilator agents, especially calcium channel
Anxiety 4 (5) 1 (1) 0.201
antagonists and low-dose dopamine, have previouslyDecreased urine output 4 (5) 2 (2) 0.434
Transient decrease in blood been evaluated for reducing the risk of radiocontrast
pressure 3 (4) 1 (1) 0.358 nephrotoxicity. In two small studies involving a total of
Light headedness 3 (4) 0 0.113
65 patients, nifedipine and nitrendipine were found toNausea 3 (4) 3 (4) 1.000
Back pain 2 (3) 2 (2) 1.000 increase renal blood flow and preserve the glomerular
filtration rate after intravascular radiocontrast adminis-
tration [25, 26], yet clinical outcome measures, such as
the incidence of radiocontrast nephrotoxicity, were notincidence of radiocontrast nephrotoxicity at 48 hours,
the relative increase was similar for both end points evaluated. Low-dose dopamine infusion has also been
observed to increase renal blood flow but was associatedamong diabetic and nondiabetic patients. The small num-
ber of nondiabetic patients may have contributed to this with a higher incidence of radiocontrast nephrotoxicity
in diabetic patients [27, 28]. It has been hypothesized thatlack of statistical significance for the effect of SB 209670,
and modeling of the interaction of these two factors vasodilators may primarily affect renal cortical blood
vessels, resulting in an intrarenal “steal” phenomenon,(treatment group and presence of diabetes) showed no
significant difference for effect of SB 209670 in diabetic which worsens renal medullary ischemia [28]. Thus, de-
spite beneficial effects on renal hemodynamics, the po-versus nondiabetic patients.
There are a number of possible reasons that SB 209670 tential role of vasodilator agents in reducing the risk
of radiocontrast nephrotoxicity remains unproved. Ourwas not efficacious for reducing the incidence of radio-
contrast nephrotoxicity. The present study involved pa- results further emphasize the discrepancy between surro-
gate markers of renal function, such as renal blood flowtients with significant chronic renal insufficiency before
cardiac angiography [mean serum creatinine 5 2.7 6 and glomerular filtration rate, and clinical outcome.
Finally, the group of patients in our study who received1.0 mg/dL (242.3 6 92.8 mmol/L)], including 63% with
diabetes mellitus. In this population, the response of intravenous saline and placebo had an incidence of radio-
contrast nephrotoxicity of 29%. This rate is somewhatthe renal vasculature to endothelin and thus endothelin
receptor antagonism may be attenuated or abnormal. higher than that reported in a recent study comparing
intravenous saline alone to diuretic therapy plus saline,Although there was a higher incidence of hypotension
in patients treated with SB 209670 and, consequently, which used the same definition and observed an 11%
incidence of radiocontrast nephrotoxicity in the saline-possible renal medullary ischemia, the mean increase in
serum creatinine for patients with this adverse effect was alone group [15]. However, the present study included
patients with higher baseline serum creatinine concentra-less than for patients who did not have hypotension.
Finally, at higher concentrations, SB 209670 has been tions and a higher percentage with diabetes mellitus. In
addition, although the mean total duration of hydrationfound to block ETB receptors [23], thus inhibiting any
potential vasodilatory effect of endothelin and possibly in our placebo group was 24 hours, the duration of hydra-
tion before radiocontrast administration was more vari-increasing plasma levels of endothelin [24].
Two broader questions are also raised by the results able compared with the prior study [15]. At present,
intravenous saline remains the most effective measureof this study: (1) the actual role of endothelin in the
pathogenesis of radiocontrast nephrotoxicity; and (2) the for reducing the risk of radiocontrast nephrotoxicity,
although the optimal amount of hydration is not known.potential benefit of any vasodilator therapy for reducing
the risk of this complication. In animal models of radio- In conclusion, the use of an intravenous mixed endo-
thelin receptor antagonist did not reduce the risk ofcontrast nephrotoxicity, endothelin receptor antagonists
increased renal blood flow and reduced renal vascular radiocontrast nephrotoxicity in patients with significant
pre-existing renal dysfunction undergoing cardiac angi-resistance after radiocontrast administration only when
the production of renal prostaglandin was concomitantly ography. Rather, patients treated with this agent and
intravenous hydration had a significantly higher inci-inhibited [9, 10]. Thus, the interactions of multiple vaso-
dilatory and vasoconstrictor influences likely determine dence of radiocontrast nephrotoxicity compared with pa-
tients treated with intravenous hydration alone. In thewhether radiocontrast nephrotoxicity occurs. Further-
more, the present study evaluated a mixed ETA and ETB future, patients treated with this novel class of therapeu-
tic agents may require close observation for the develop-receptor antagonist, and it is unknown whether selective
ETA blockade may be beneficial in preventing radiocon- ment of nephrotoxicity after radiocontrast administra-
tion. Further studies of therapies for the prevention oftrast nephrotoxicity. Despite these considerations, the
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